Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:SCYX

SCYNEXIS Q4 2025 Earnings Results & Report

SCYNEXIS logo
$3.33 -0.08 (-2.35%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$3.32 -0.01 (-0.30%)
As of 11/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 4, 2026. The company reported EPS of $2.00 versus the $2.32 consensus estimate, while revenue of $17.20 million topped the $8.10 million estimate by $9.10 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

SCYNEXIS EPS Results

Actual EPS
$2.00
Consensus EPS
$2.32
Beat/Miss
Missed by -$0.32
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

SCYNEXIS Revenue Results

Actual Revenue
$17.20 million
Expected Revenue
$8.10 million
Beat/Miss
Beat by +$9.10 million
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

SCYNEXIS's Q4 2025 Press ReleasePress Release
(8-K)
SCYNEXIS's Q4 2025 Annual reportAnnual report
(10-K)

SCYNEXIS Q4 2025 Earnings FAQ

SCYNEXIS (NASDAQ:SCYX) reported earnings of $2.00 per share for Q4 2025, missing the consensus estimate of $2.32. The report was announced on Wednesday, March 4, 2026.

SCYNEXIS reported revenue of $17.20 million for Q4 2025, against a consensus estimate of $8.10 million.

SCYNEXIS Earnings Headlines

FY2026 EPS Forecast for SCYNEXIS Reduced by Analyst
November 12 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192863
SCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program Advances
November 10 at 4:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190292
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
 |  Profits Run (Ad)
SCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street Zen
November 10 at 2:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189009
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396422/0/en/scynexis-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391192/0/en/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference.html
See More SCYNEXIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email.

About SCYNEXIS

SCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis. It is also approved to reduce the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females. Unlike azole antifungals, ibrexafungerp belongs to a different structural class and is being developed to address infections involving fungi that may be resistant to existing treatments.

The company is also evaluating ibrexafungerp for additional indications, including certain invasive fungal infections, and has pursued opportunities to expand the product’s use through clinical development and commercial collaborations. SCYNEXIS is headquartered in Jersey City, New Jersey, and its principal commercial focus has been the United States, where BREXAFEMME is marketed for approved indications.

View SCYNEXIS Profile
Earnings Tools